News

BIAL launches KYNMOBI® in Germany

The first sublingual therapy for the on-demand treatment of OFF episodes in Parkinson’s diseas

03/05/2024

BIAL appoints Pierluigi Antonelli as Non-Executive Board Member

BIAL appoints Pierluigi Antonelli as Non-Executive Board Member

24/04/2024

BIAL celebrates its centenary in 2024

BIAL celebrates its centenary in 2024. Initiatives planned throughout the year will establish relationships with employees, partners and the community.

20/03/2024

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

07/12/2023

BIAL to discuss scientific advances in Epilepsy

BIAL to discuss scientific advances in Epilepsy

09/08/2023

BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156

BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson’s Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene.

25/05/2023

BIAL Appoints Melanie Lee As Non-Executive Board Member

BIAL Appoints Melanie Lee As Non-Executive Board Member

22/05/2023

BIAL appoints Max Bricchi as Chief Commercial Officer

BIAL has announced the appointment of Max Bricchi as Chief Commercial Officer (CCO) and Executive Board member.

21/04/2023

Scientist.com Announces Launch of Research Marketplace for BIAL

PScientist.com Announces Launch of Research Marketplace for BIAL BIAL partners with Scientist.com to improve and digitize internal R&D

11/01/2023